Antiarrhythmic versus control: study Excluded of the Systematic review
DISEASE INTERVENTION COMPARISON RESULTS
Circ Arrhythm Electrophysiol. 2011 Oct;4(5):637-43 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, Study ID: Torp-Pedersen 2011 The Use of
vernakalant
As Treatment, Chronic
Is better Than
placebo
To reduce AF recurrence at 3 months, at the cost of several serious events associated (3 patients)
Am Heart J. 2002 Oct;144(4):597-607 Randomized Controlled Trial
IN Study ID: AF-CHF 2008 (subordinated publication), atrial fibrillation, rate control strategy, heart failure, chronic, systolic The Use of
rhythm control: electrical cardioversion combined with antiarrhythmic drugs (amiodarone or other class III agents)
As Treatment, Chronic
Is undefined Than
rate control
To primary end point : cardiovascular mortality (protocol for a RCT)
N Engl J Med. 2008 Jun 19;358(25):2667-77 Randomized Controlled Trial, Multicenter Study
IN Study ID: AF-CHF 2008, atrial fibrillation, rate control strategy, heart failure, chronic, systolic The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control strategy
To modify death from cardiovascular causes (25% rate-control VS 27% rhythm-control) or reduce stroke (4% rate-control VS 3% rhythm-control) or worsening heart failure (31% rate-control VS 28% rhythm-control)
Circ J. 2009 Feb;73(2):242-8 Randomized Controlled Trial
IN Study ID: J-RHYTHM 2009, atrial fibrillation, persistent, rate control strategy The Use of
rate control strategy
As Treatment, Chronic
Is equal Than
rhythm control
To modify mortality and cardiovascular morbidity at 1.5 years
Nord Med. 1968 Jun 13; 79(24): 781-2 Controlled Clinical Trial
IN StudyID: Aberg 1969 (subordinated publication), atrial fibrillation The Use of
procaine amide quinidine (?)
As Treatment, Chronic
Is not available Than
not available
To AF recurrence
Nord Med. 1969 Aug 14;82(33):1011-3 Controlled Clinical Trial
IN StudyID: Aberg 1969, atrial fibrillation The Use of
procaine amide quinidine (?)
As Treatment, Chronic
Is not available Than
not available
To not available
N Engl J Med. 2002 Dec 5;347(23):1825-33 Randomized Controlled Trial
IN StudyID: AFFIRM 2002, atrial fibrillation, rate control strategy The Use of
rate control strategy (drugs and anticoagulation)
As Treatment, Chronic
Is equal Than
rhythm control strategy (cardioversion and antiarrhythmics, anticoagulation recommended)
To overall mortality: 4,26%/year in rate-c vs 4,76%/year in rhythm-c. More patients in rhythm-c were hospitalized and suffered adverse drug effects
Circulation. 1989 Dec; 80(6): 1557-70 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Anderson 1994 (subordinate publication), atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 4 months
Am J Cardiol. 1992;70(5):11A-17A Randomized Controlled Trial
IN StudyID: Anderson 1994 (subordinate publication), atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 4 months
Am J Cardiol. 1994;74(6):578-84 Cross-Over
IN StudyID: Anderson 1994, atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 4 months
J Am Coll Cardiol. 1988 Oct;12(4):1005-11 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Antman 1990 (subordinated publication), atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 6 months
J Am Coll Cardiol. 1990 Mar 1;15(3):698-707 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Antman 1990, atrial fibrillation The Use of
propafenone, sotalol if failure, sequentially
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 6 months
Rev Esp Cardiol. 1978;31(1 Pt 2):185-91 Randomized Controlled Trial
IN StudyID: Aros 1978, atrial fibrillation The Use of
quinidine plus amiodarone
As Treatment, Chronic
Is better Than
quinidine alone
To not available
Am J Cardiol. 1987 Jun 1;59(15):1337-41 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Berns 1987, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, proarrhytmie, adverse effects - at 6 months
Arch Intern Med. 1987 Aug;147(8):1401-4 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Blevins 1987, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Acute, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 16 Months
Acta Med Scand. 1984;216(5):517-24 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Blomstrom 1984, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
Eur Heart J. 1981 Feb; 2(1): 49-55 not available
IN StudyID: Boissel 1981, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is - Than
not available
To not available
Am J Cardiol. 1987 Sep 1;60(7):572-5 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Brodsky 1987, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 12 Months
Circulation. 1998 Dec 8;98(23):2574-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: CHF-STAT 1998, atrial fibrillation, heart failure The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To mortality, AF recurrence - at 12 months
Am J Cardiol. 1995 Jul 1;76(1):47-50 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Chun 1995, atrial fibrillation, paroxysmal, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no control group
To mortality, adverse effects, proarrhythmia, AF recurrence - at 12 months
Am J Cardiol. 1992 Aug 20;70(5):44A-49A Clinical Trial (non-controlled, non-randomized)
IN StudyID: Clementy 1992, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is - Than
no comparison
To mortality, AF recurrence, proarrhytmie, adverse effects - at 9 months
Am J Cardiol. 1989 Apr 1;63(12):817-9 Cross-Over
IN StudyID: Connolly 1989, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone
As Treatment, Chronic
Is equal Than
placebo
To AF symptomatic recurrence
Arch Inst Cardiol Mex. 1971 May-Jun; 41(3): 278-84 Not available
IN StudyID: Cuan-Perez 1971, atrial fibrillation The Use of
quinidine, diphenylhydantoin
As Treatment, Chronic
Is - Than
propranolol
To Not available
Am J Cardiol. 2002 Dec 15;90(12):1300-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: ERAFT 2002, atrial fibrillation, paroxysmal The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse events - at what time?
Minerva Med. 1970 Sep 5; 61(71 Suppl): 3745-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Faivre 1970, atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is useful Than
retrospective series of different AA
To Not available
Rev Esp Cardiol. 1998;51(Suppl 5):84 Randomized Controlled Trial
IN StudyID: Fernandez 1998, atrial fibrillation, paroxysmal The Use of
amiodarone, flecainide
As Treatment, Acute
Is - Than
propafenone
To acute revers atrial fibrillation to sinus rhythm
Am J Cardiol. 1986 Jan 1;57(1):124-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Gold 1986, atrial fibrillation, persistent, rejected The Use of
Amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
JAMA. 1992 Jun 24; 267(24): 3289-93 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Gosselink 1992, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is useful Than
no controls
To AF recurrence, adverse effects - at 3 years
Am Heart J. 1983 Oct;106(4 Pt 2):870-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Graboys 1983, atrial fibrillation, paroxysmal, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 27,3 Months
Am J Cardiol. 1988 Feb 15;61(6):473-4 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Hammil 1988, atrial fibrillation, persistent The Use of
propafenone
As unknow
Is - Than
unknow
To unknow
Klinische Wochenschrift. 1969;47(17):942 not available
IN StudyID: Hartel 1970 (subordinated publication), atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is not available Than
not available
To not available
Die Medizinische Welt. 1969;20(25):1464 not available
IN StudyID: Hartel 1970 (subordinated publication), atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is not available Than
not available
To not available
Br Heart J 1970 Jan;32(1):57-60 not available
IN StudyID: Hartel 1970, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is - Than
not available
To not available
Clin Pharmacol Ther. 1974 Jun; 15(6): 551-5 Controlled Clinical Trial
IN StudyID: Hartel 1974, atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is - Than
not available
To AF recurrence, not available
Am J Cardiol. 1996 Jan 25;77(3):72A-82A Clinical Trial (non-controlled, non-randomized)
IN StudyID: Hopson 1996 (former FSTS), atrial fibrillation, rejected The Use of
flecainide
As Treatment, Chronic
Is - Than
non controlled
To arrhytmia recurrence, pro-arrhytmia, adverse effects
J Am Coll Cardiol. 1985 Dec;6(6):1402-7 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Horowitz 1985, atrial fibrillation, persistent, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects - at 15 months
Kardiol Pol. 2003 Jul;59(7):1-16; discussion 15-16 Randomized Controlled Trial
IN StudyID: HOT-CAFE 2004 (subordinated publication), atrial fibrillation, persistent The Use of
various antiarrhythmics
As Treatment, Chronic
Is equal Than
rate control
To mortality, stroke, heart failure, AF recurrence, adverse effects - at 1 year
Pol Arch Med Wewn. 1999 May;101(5):413-8 Randomized Controlled Trial
IN StudyID: HOT-CAFE 2004 (subordinated publication), atrial fibrillation, persistent The Use of
various antiarrhythmics
As Treatment, Chronic
Is equal Than
rate control
To mortality, stroke, heart failure, AF recurrence, adverse effects - at 1 year
Chest. 2004 Aug;126(2):476-86 Randomized Controlled Trial, Multicenter Trial
IN StudyID: HOT-CAFE 2004, atrial fibrillation, persistent The Use of
various AA
As Treatment, Chronic
Is worse Than
rate control
To mortality, stroke, heart failure, AF recurrence, adverse effects - at 1 year
Circ J. 2009 Jun;73(6):1020-7 Randomized Controlled Trial
IN StudyID: J-BAF 2009, atrial fibrillation, persistent The Use of
bepridil
As Treatment, Chronic
Is worse Than
placebo
To modify outcomes at 3 months: higher cardioversion to SR with bepridil but high recurrence of AF and significant pro-arrhythmia
Chin Med J (Engl). 2006 Dec 20;119(24):2030-5 Randomized Controlled Trial
IN StudyID: Jong 2006, antiarrthythmic drugs, amiodarone, pharmacokinetics, very low dose maintenance The Use of
amiodarone, very low dose, 100 mg/d
As Treatment, Chronic
Is equal Than
amiodarone, usual low dose, 200 mg/d
To maintain sinus rhythm at 5 year, after cardioversion of atrial fibrillation: 42% with 200mg/d VS 36% with 100 mg/d. Less adverse effects in the lower dose.
Am J Cardiol. 2004 Sep 1;94(5):659-62 Randomized Controlled Trial
IN StudyID: Kanoupakis 2004, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 4 weeks
Am J Cardiol. 1988 Apr 15;61(11):914-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kerr 1988, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is - Than
not available
To not available
Medical Science Monitor 2001 Jan-Feb;7(1):68-73 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kosior 2002 (subordinated publication), atrial fibrillation, rejected The Use of
various AARs
As Treatment, Chronic
Is - Than
no control
To AF recurrence
Kardiol Pol. 2002;56(4):361-367 Randomized Controlled Trial
IN StudyID: Kosior 2002 (subordinated publication), atrial fibrillation, rejected The Use of
various AARs, sequential antiarrhythmic therapy
As Treatment, Chronic
Is better Than
no control
To AF recurrence - at 1 year
Pol Arch Med Wewn. 2002 Dec;108(6):1151-60 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kosior 2002, atrial fibrillation, rejected The Use of
various AARs
As Treatment, Chronic
Is - Than
no control
To AF recurrence
Can J Cardiol. 1991 Nov;7(9):407-9 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Kyles 1991, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 30 months
Minerva Cardioangiol. 1973 Oct; 21(10): 668-71 Clinical Trial
IN StudyID: Levi 1973 (subordinated publication), atrial fibrillation The Use of
quinidine
As Treatment, ?
Is - Than
practolol
To Not available
Cardiology. 1973; 58(6): 364-8 Randomized Controlled Trial
IN StudyID: Levi 1973, atrial fibrillation The Use of
quinidine plus beta-blocker (practolol)
As Treatment, Acute
Is equal Than
quinidine alone
To acute pharmacological cardioversion of AF
Am J Cardiol. 2004 Jan 1;93(1):45-8 Randomized Controlled Trial?
IN StudyID: Li 2004, atrial fibrillation, persistent The Use of
diverse AAR
As Treatment, Chronic
Is equal Than
rate control drugs
To AF recurrence - at 1 month
Cardiovasc Drugs Ther. 2003 Jan;17(1):31-39 Randomized Controlled Trial
IN StudyID: Manios 2003, atrial fibrillation, rejected The Use of
amiodarone
As Treatment, Chronic
Is better Than
diltiazem, no treatment
To AF recurrence - at 6 weeks
Cardiology. 1990;77(6):443-9 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Mary-Rabine 1990, atrial fibrillation, paroxysmal, persistent, rejected The Use of
flecainide
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
Japanese Pharmacology and Therapeutics. 1995;23(7):113-120 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Mizutani 1995, atrial fibrillation, paroxysmal The Use of
pilsicainide
As Treatment, Chronic
Is bad Than
no controls
To mortality, AF recurrence, adverse effects, pro-arrythmia - at 8 months
Clin Cardiol. 1997 Apr;20(4):337-40 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Opolski 1997, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 12 months
Arch Mal Coeur Vaiss. 2002 Jun;95(6):567-72 Clinical Trial (non-controlled, non-randomized)
IN StudyID: PEPS 2002, atrial fibrillation, rejected The Use of
propafenone
As Treatment, Chronic
Is useful Than
not controlled
To AF recurrence, adverse effects, pro-arrhythmia - at 12 months
Eur Heart J. 2003 Aug;24(15):1430-6 Randomized Controlled Trial
IN StudyID: PIAF 2000 (subordinated publication), atrial fibrillation, rate control strategy, functional status The Use of
rhythm control strategy (amiodarone)
As Treatment, Chronic
Is equal Than
rate control strategy (verapamil and anticoagulation)
To impact on quality of life - at 1 year
Lancet. 2000 Nov 25;356(9244):1789-94 Randomized Controlled Trial
IN StudyID: PIAF 2000, atrial fibrillation, rate control strategy The Use of
rhythm control strategy (amiodarone)
As Treatment, Acute
Is equal Than
rate control strategy (verapamil and anticoagulation)
To improvement in symptoms related to atrial fibrillation. Exercise tolerance is better with rhythm control, although hospital admission is more frequent. Only 23% patients in amiodarone were in sinus rhythm at 1 year.
Am J Cardiol. 1991 Apr 1;67(8):713-717 Randomized Controlled Trial
IN StudyID: Pietersen 1991, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, mortality - at 3 months
Am J Cardiol. 1989 Jan 1;63(1):114-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Porterfield 1989, atrial fibrillation, persistent The Use of
propafenone
As unknow
Is - Than
unknow
To unknow
Circulation. 1995 Nov 1;92(9):2550-7 Randomized Controlled Trial
IN StudyID: PSVT 1995, atrial fibrillation, rejected The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at ? Time
N Engl J Med. 2002 Dec 5;347(23):1834-40 Randomized Controlled Trial
IN StudyID: RACE 2002, atrial fibrillation, rate control strategy The Use of
rate control strategy (drugs and anticoagulation)
As Treatment, Chronic
Is equal Than
rhythm control strategy (electrical cardioversion and antiarrhythmics, anticoagulation recommended)
To combined events (cardiovascular death, heart failure, any embolism, bleeding, severe drug adverse effects, pacemaker): 3,44%/year in rate-c vs 4,52%/year in rhythm-c. Patients in sinus rhythm at 2,3 years were 10% in rate-c vs 39% in rhythm-c
Acta Med Scand Suppl. 1981; 645: 23-8 Cross-Over, Randomized Controlled Trial
IN StudyID: Rasmussen 1981, atrial fibrillation, rejected The Use of
quinidine
As Treatment, Chronic
Is better Than
verapamil
To AF recurrence, adverse effects, sudden death
Br Heart J 1971 Mar;33(2):220-5 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Resnekov 1971, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is equal Than
no treatment
To avoid AF recurrence, and worse for adverse effects
J Am Coll Cardiol. 2003 May 21;41(10):1690-6 Randomized Controlled Trial
IN StudyID: STAF 2003, atrial fibrillation, rate control strategy The Use of
rate control strategy (pharmacologic or invasive rate-control and anticoagulation)
As Treatment, Chronic
Is equal Than
rhythm control strategy (restoration and maintenance of sinus rhythm)
To combined major cardiovascular events (death, heart arrest, stroke, and systemic embolism): 6.09%/year in rate-c vs 5.54%/year in rhythm-c. Patients in sinus rhythm at 3 years were 0% in rate-c vs 23% in rhythm-c
Heart. Aug 1999; 82(2):170-5 Cross-Over, Randomized Controlled Trial
IN StudyID: Steeds 1999, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is equal Than
atenolol
To at 1 month: AF recurrence, adverse effects
Ital Heart J 2001 Mar;2(3 Suppl):322-3 Randomized Controlled Trial
IN StudyID: Vergara 2001 (get full text), atrial fibrillation The Use of
dofetilide
As Treatment, Chronic
Is - Than
Not available
To Not available
Am Heart J. 1997 Apr;133(4):441-6 Randomized Controlled Trial
IN StudyID: Wanless 1997, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is better Than
placebo
To time to arrhythmia/AF recurrence, adverse effects - at ? time